drugset / Trial / NCT03663881

Safety Assessment of P2Et Extract in Healthy Voluntary Subjects in Colombia

NCT03663881 ↗

NaSingle-groupOpen-labelTreatment

Summary

Caesalpinia spinosa extract is rich in gallotannins and other well characterized polyphenols and has a major antioxidant activity. The extract shows immunomodulatory activity in healthy animals and anti-tumor activity in animals with breast cancer and melanoma as well. The use of P2Et in animals with tumors shows a synergistic effect with doxorubicin in drug-resistant cell lines. In addition, an increase in survival of transplanted animals with a TS/A breast cancer tumor model and treated with P2Et, in conjunction with calreticulin increase is observed. This open-label, single arm, Phase 1 study intends to assess the safety of P2Et extract obtained from Caesalpinia spinosa, with dose escalation, in healthy voluntary participants in Colombia.

Timeline

Start
2019-04-30
Primary completion
2020-05-15
Completion
2020-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject P2Et extract Unknown 600 mg Oral
Subject P2Et extract Unknown 1200 mg Oral
Subject P2Et extract Unknown 2400 mg Oral
Subject P2Et extract Unknown 4800 mg Oral

Indications